Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | FDPS | P14324 | 3/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745316 | 1.00 | DNM1 (0.57) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL18400723 | 1.00 | DNM1 (0.57) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL19706306 | 0.98 | DNM1 (0.55) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL20848071 | 0.97 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL21014622 | 0.95 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL24064593 | 0.95 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL11008977 | 0.92 | DNM1 (0.60) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL18612349 | 0.91 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL8966392 | 0.91 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL26038955 | 0.91 | DNM1 (0.59) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | DNM1 710/4885TSHR 4286/4885MEN1 894/4885 |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | LNPEP, DNPEP, QPCT | DNM1 1891/4885TSHR 1171/4885MEN1 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.